The DAPT score was developed to identify patients more likely to derive harm (score <2) or benefit (score ≥2) from prolonged DAPT after PCI. The reduction in the primary efficacy outcome with 24- vs 6-month DAPT was greater in patients with high scores (risk difference [RD] for score ≥2, −2.05% [95% CI −5.04 to 0.95 percentage points]; RD for score <2, 2.91% [CI −0.43 to 6.25 percentage points]; P = 0.030).